Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 1477Neoplasms 999Colorectal Neoplasms 832Carcinoma, Non-Small-Cell Lung 724Carcinoma, Hepatocellular 683Stomach Neoplasms 648Lung Neoplasms 584Prostatic Neoplasms 543Pancreatic Neoplasms 456Rectal Neoplasms 339Uterine Cervical Neoplasms 303Colonic Neoplasms 295Neoplasm Metastasis 294Ovarian Neoplasms 285Esophageal Neoplasms 279Recurrence 278Leukemia, Myeloid, Acute 253Head and Neck Neoplasms 241Multiple Myeloma 232Brain Neoplasms 204Polycystic Ovary Syndrome 200Nasopharyngeal Carcinoma 198Melanoma 198Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Urinary Bladder Neoplasms 193Lymphoma 178Liver Neoplasms 178Endometrial Neoplasms 159Motor Activity 147Lymphoma, Large B-Cell, Diffuse 141

Interventions

trifluridine tipiracil drug combination 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × First-line Treatment × Clear all
NCT05221775 2022-02-03

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
18 enrolled
Gastrointestinal

First-line Treatment

NCT05077839 2021-10-25

TOBACO

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
184 enrolled
Gastrointestinal

First-line Treatment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡